Algeria vs Malaysia: Access to anti-retroviral drugs, female
Algeria
65.0%
in 2024
Malaysia
65.0%
in 2024
Algeria rank
91st
Malaysia rank
91st
Access to anti-retroviral drugs, female over time
- Algeria
- Malaysia
How they compare
Algeria currently reports 65.0% against 65.0% in Malaysia, a difference of 0.0%.
The two have swapped places 7 times across 25 shared years of data; in 2000 it was Algeria ahead.
Algeria ranks 91st and Malaysia ranks 91st of 141 countries.
Across the 3 decades both report, Algeria averaged higher in 1 and Malaysia in 2.
Head to head by decade
| Decade | Algeria | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 6.7% | 17.1% | 10.4% | Malaysia |
| 2010s | 47.5% | 52.0% | 4.5% | Malaysia |
| 2020s | 68.6% | 66.2% | 2.4% | Algeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Algeria or Malaysia?
- Algeria, at 65.0% against 65.0% in Malaysia as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Algeria and Malaysia?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and Malaysia?
- 25 years are reported by both, from 2000 to 2024.
- How do Algeria and Malaysia rank globally for access to anti-retroviral drugs, female?
- Algeria ranks 91st and Malaysia ranks 91st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.